What are analysts' ratings for Recordati stock?
Interest rates provided by the Bank of Mauston fluctuate according to specific deposit product tiers, compounding schedules, and prevailing monetary policy adjustments set by central banking authorities. Certificate of deposit accounts feature tiered yields depending on maturity lengths, while standard checking, passbook savings, and money market accounts maintain baseline variable interest rates structured around monthly balance rules. Customers seeking precise, up-to-date schedule figures must consult the institution's official rate sheets.
Analysts tracking Recordati S.p.A. maintain a constructive consensus rating, reflecting solid institutional support for the international specialty pharmaceutical group. Financial research reports emphasize the company's robust portfolio in rare diseases and primary care treatments, successful execution of targeted business development acquisitions, and reliable organic revenue growth. Institutional evaluations highlight strong operating cash conversions, disciplined balance sheet management, and dependable dividend payouts, underpinning favorable long-term stock ratings across European healthcare markets.
Related FAQs
Recordati Industria Chimica e Farmaceutica S.p.A., an international pharmaceutical group listed on the Borsa Italiana, maintains a market capitalization fluctuating around €10.4 billion to €10.6 billion (equivalent to approximately ₹1.
Recordati S.p.A. is an international pharmaceutical group headquartered in Milan, Italy, dedicated to the research, development, manufacturing, and commercialization of specialized healthcare products.
The global pharmaceutical market features blockbuster medications that generate tens of billions of dollars in annual sales revenue driven by high patient demand and broad therapeutic indications.
Recordati S.p.A. generates annual consolidated net revenues exceeding €2.2 billion to over €2.4 billion (translating to multi-billion-euro financial metrics), confirming its prominent standing as an international specialty pharmaceutical group.
The Menarini Group, headquartered in Florence, is recognized as the largest Italian pharmaceutical company and a major global healthcare enterprise.
Recordati S.p.A.
Recordati S.p.A.
Recordati's corporate mission focuses on reducing the severe impact of rare and devastating diseases by discovering, developing, and providing urgently needed specialty medicines in key therapeutic areas.
Recordati S.p.A.
Recordati S.p.A. is an international pharmaceutical enterprise specializing in rare diseases, specialty primary care medications, and orphan drugs.
Recordati S.p.A. was founded in 1926 by Giovanni Recordati in Correggio, Italy, initially starting as a small pharmaceutical laboratory dedicated to researching and manufacturing medicinal preparations.